Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × vandetanib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 28 Head & Neck 14 Gastrointestinal 13 CNS 13 Genitourinary 10 Breast 9 Endocrine 7 Tumor-Agnostic 6 Sarcoma 5 Other solid neoplasm 3 Gynecologic 3 Plasma cell 1 Other neoplasm 1 Other hematologic neoplasm 1 NET 1 Lymphoid 1 Dermatologic 1

Conditions

Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 41 Everolimus 38 Magnetic Resonance Spectroscopy 18 Temozolomide 17 lanreotide 16 gallium Ga 68 dotatate 15 Octreotide 14 pembrolizumab 13 Nivolumab 13 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 surufatinib 9 pasireotide 9 Sunitinib 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 Lutetium-177 8 Carboplatin 8 amino-acid, glucose, and electrolyte solution 6 Ipilimumab 6 Ga(III)-DOTATOC 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 copper dotatate CU-64 5 Injections 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡